Zhan Huichun, Zheng Haoyi
Department of Medicine, Long Island Jewish Medical Center, Albert Einstein College of Medicine, New Hyde Park, New York 11040, USA.
Am J Clin Dermatol. 2007;8(4):195-200. doi: 10.2165/00128071-200708040-00002.
Cyclo-oxygenases (COXs) are rate-limiting enzymes in arachidonic acid metabolism and prostaglandin production. COX-2 is the main UV-responsive COX isoform in human skin and is involved in UV-induced skin inflammation and apoptosis. The topical NSAID diclofenac works as a nonspecific COX inhibitor and is an effective and well tolerated treatment for actinic keratosis, which is a principal precursor of cutaneous squamous cell carcinoma. Oral and topical COX-2 inhibitors have chemopreventive activity against chemically and UV light-induced skin cancer in animal models. The mechanism of action of COX inhibitors in skin tumorigenesis is complex and not completely understood. Clinical trials to evaluate whether topical administration of NSAIDs or specific COX-2 inhibitors can prevent skin cancer in high-risk patients are warranted.
环氧化酶(COXs)是花生四烯酸代谢和前列腺素生成中的限速酶。COX-2是人类皮肤中主要的紫外线反应性COX同工型,参与紫外线诱导的皮肤炎症和细胞凋亡。局部使用的非甾体抗炎药双氯芬酸作为一种非特异性COX抑制剂,是治疗光化性角化病的有效且耐受性良好的药物,光化性角化病是皮肤鳞状细胞癌的主要前驱病变。在动物模型中,口服和局部使用的COX-2抑制剂对化学诱导和紫外线诱导的皮肤癌具有化学预防活性。COX抑制剂在皮肤肿瘤发生中的作用机制复杂,尚未完全明确。有必要进行临床试验,以评估局部使用非甾体抗炎药或特异性COX-2抑制剂能否预防高危患者的皮肤癌。